Trump Administration Pushes to Let Specialty Pharmacies Make Peptide Injections

The U.S. Department of Health and Human Services has moved forward with an interim access policy that would let specialty pharmacies produce certain peptides, a move that follows growing demand from health‑seeking consumers and wellness influencers. Peptides—small proteins that can trigger hormones for growth, metabolism and healing—have been sold online without the FDA’s rigorous testing. The policy, submitted to the White House and reviewed by the Office of Management and Budget, allows compounding pharmacies to make selected peptides.

Specialty Pharmacies Get Leeway

Under the policy, the FDA would exercise enforcement discretion, meaning compounding pharmacies would not face penalties for making selected peptides such as BPC‑157, which is promoted for muscle building and injury repair. The agency had earlier placed BPC‑157 and other peptides on a list of substances too risky for compounding. The new approach signals a shift toward allowing the production of popular but unproven products.

Brigham Buhler, a wellness clinic operator who sells peptides online, said on X, “This is huge. This isn’t about whether you’re for or against peptides. It’s about whether you’re for or against MEDICAL FREEDOM.” The July advisory panel that Kennedy’s health department convened recommended lifting restrictions on six of seven peptides, a recommendation that contradicted the FDA’s own scientific assessment. Telehealth companies such as Hims & Hers and Noom have said they plan to offer peptides to customers if the government eases access, and the market could be worth $2 billion to $3 billion.